AXQ Capital’s Coherus Oncology CHRS Stock Holding History

AXQ Capital’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-15,465	Closed	-$106K	–	333
2023 Q1	$106K	Buy	+15,465	New	+$120K	0.04%	441

Other funds holding CHRS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACB

Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

AXQ Capital's CHRS Position: Q2 2023 in Review

AXQ Capital sold out of Coherus Oncology (CHRS) in Q2 2023, closing a stake of 15,465 shares — an estimated $106K sold.

AXQ Capital first reported a position in CHRS in Q1 2023 and held it in 1 quarter. The position peaked at $106K in Q1 2023. 161 funds tracked by Wall St. Rank hold CHRS as of Q2 2023.

AXQ Capital reported no remaining Coherus Oncology position as of Q2 2023 after selling out during the quarter.
AXQ Capital sold 15,465 Coherus Oncology shares in Q2 2023, an estimated $106K.
AXQ Capital first reported a position in Coherus Oncology in Q1 2023 and held it in 1 quarter.
AXQ Capital's Coherus Oncology position peaked at $106K in Q1 2023.
161 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2023.

Based on AXQ Capital's 13F filing for Q2 2023, filed 11 Aug 2023.